Please login to the form below

Not currently logged in
Email:
Password:

aspirin

This page shows the latest aspirin news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca’s Brilinta reduces rate of secondary stroke

AstraZeneca’s Brilinta reduces rate of secondary stroke

Detailed results from the phase 3 THALES trial also showed that Brilinta, given at a dose of 90mg twice-daily alongside aspirin, significantly reduced the rate of ischaemic stroke by 21%, ... The drug also reduced the risk for severe bleeding events –

Latest news

  • AZ says Brilinta hits the mark in new stroke trial AZ says Brilinta hits the mark in new stroke trial

    This time round, AZ evaluated Brilinta (ticagrelor) at a dose of 90-mg twice-daily, taken with aspirin for 30 days, in the phase 3 THALES trial. ... AZ has already tried to prove Brilinta’s benefit over aspirin in preventing stroke, but failed to do so

  • AZ unveils phase 3 Brilinta data in CAD and type 2 diabetes AZ unveils phase 3 Brilinta data in CAD and type 2 diabetes

    The study demonstrated that Brilinta plus aspirin reduced the risk of cardiovascular death, heart attack or stroke by 10% compared to aspirin alone.

  • AZ says Brilinta hits the mark in diabetic heart disease AZ says Brilinta hits the mark in diabetic heart disease

    The study showed that in diabetics with CAD and no prior history of heart attack or stroke, Brilinta given on top of aspirin therapy achieved a statistically-significant reduction in a ... Last year, the GLOBAL LEADERS study last year also showed that

  • Xarelto no better than aspirin in secondary stroke study Xarelto no better than aspirin in secondary stroke study

    low-dose aspirin, which is commonly prescribed for this purpose, but failed to hit the mark at the interim stage. ... While bleeding rates were low overall, an increase in bleeding was observed in the rivaroxaban arm compared to the low dose aspirin arm,

  • Xarelto beats aspirin for recurrent blood clots Xarelto beats aspirin for recurrent blood clots

    A new phase III trial shows that Bayer and Janssen's novel oral anticoagulant (NOAC) Xarelto is more effective than aspirin at preventing recurrent blood clots, with no increase in bleeding ... It's already known that after an initial few months of

More from news
Approximately 1 fully matching, plus 71 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Natasha Giordano joins PLx Pharma Natasha Giordano joins PLx Pharma

    We are confident Natasha will be a driving force for PLx as we transition from the development phase to the commercial launch of our lead product, PL2200 Aspirin.”. ... I look forward to building on the compelling clinical data and initial market

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
...
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics